Cortexyme (NASDAQ:CRTX – Get Free Report) and SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Volatility and Risk
Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Valuation & Earnings
This table compares Cortexyme and SpringWorks Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Earnings Per Share
This is a summary of recent ratings for Cortexyme and SpringWorks Therapeutics, as reported by MarketBeat.com.
|Strong Buy Ratings
SpringWorks Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 19.02%. Given SpringWorks Therapeutics’ higher probable upside, analysts plainly believe SpringWorks Therapeutics is more favorable than Cortexyme.
Insider & Institutional Ownership
63.2% of Cortexyme shares are held by institutional investors. 27.9% of Cortexyme shares are held by company insiders. Comparatively, 7.4% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Cortexyme and SpringWorks Therapeutics’ net margins, return on equity and return on assets.
|Return on Equity
|Return on Assets
Cortexyme beats SpringWorks Therapeutics on 6 of the 10 factors compared between the two stocks.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.